PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

October 31, 2012

Study Completion Date

January 31, 2013

Conditions
Rheumatoid Arthritis
Interventions
DRUG

pioglitazone

daily dose, 30 mg daily for 2 weeks followed by 45 mg daily until completing 3 months unless higher dose not tolerated in which case patient remained at 30 mg daily

DRUG

Sublingual nitroglycerine

Used during nitroglycerin-mediated dilatation vascular function measures in both arms of the study if patient's blood pressure permitted. One single tablet was used per vascular test performed.

Trial Locations (1)

48109

University of Michigan, Ann Arbor

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Michigan

OTHER

NCT00554853 - PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease | Biotech Hunter | Biotech Hunter